MedTrace Logo

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions

NCT06638541 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-03-23

No results posted yet for this study

Summary

DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT). All radiotherapy will be delivered in two fractions (sessions) on an MR Linac using daily adaptation. Men will either receive uniform dose radiotherapy or de-escalated dose radiotherapy. The primary endpoint is acute GU CTCAE v5 grade 2+ toxicity. It will also look at late toxicity, patient-reported outcome measures and PSA control.

Conditions

Interventions

RADIATION

Prostate radical radiotherapy

Radiation: De-escalated radiotherapy to be delivered on the Elekta Unity MR-linac

Sponsors & Collaborators

  • Elekta Limited

    collaborator INDUSTRY

  • MRL Consortium

    collaborator UNKNOWN

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Alison Tree · Royal Marsden Hospital, Institute of Cancer Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-20
Primary Completion
2027-01-01
Completion
2027-01-01

Countries

  • Canada
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06638541 on ClinicalTrials.gov